Gilead Sciences: Diabetes Mellitus, Type 2 trials

The registry lists 12 Diabetes Mellitus, Type 2 studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 3Phase 2 4Phase 3 4Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin AloneCompletedNCT01555164Phase 3Results posted
• Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes MellitusCompletedNCT01494987Phase 3Results posted
• Ranolazine Monotherapy in Subjects With Type 2 Diabetes MellitusCompletedNCT01472185Phase 3Results posted
• Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable AnginaCompletedNCT01425359Phase 4Results posted
• Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic TherapyCompletedNCT01163721Phase 2Results posted
• A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.CompletedNCT01843127Phase 1
• Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With RanolazineCompletedNCT01546597Phase 1
• Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mgCompletedNCT01546558Phase 1
• A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)WithdrawnNCT01334203Phase 4
• Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on MetforminTerminatedNCT00814372Phase 2
• Safety and Tolerability Study of MBX-2044 in Patients With Type 2 DiabetesCompletedNCT00422487Phase 2
• Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on InsulinCompletedNCT00353587Phase 2/3